Celgene to Acquire Quanticel Pharmaceuticals
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/2/2026
- Wall St set to open higher after June jobs report eases rate hike bets
- Oil falls to four-month low as US, Iran conclude talks in Doha
- Bond prices and stocks rally on softer payrolls, dollar falls
- Meta Platforms stock surges 8% on cloud business plans
- Humanoid robot component stocks surge on supply-chain optimism
Celgene (CELG) to Acquire Quanticel Pharma in $485M Deal
April 27, 2015 7:31 AM EDTCelgene (NASDAQ: CELG) and Quanticel Pharmaceuticals, Inc., a privately held biotechnology company focused on cancer drug discovery, today announced a definitive share purchase agreement under which Celgene Corporation will acquire Quanticel. Through the agreement, Celgene will have full access to Quanticels proprietary platform for the single-cell genomic analysis of human cancer, as well as Quanticels lead programs that target specific epigenetic modifiers to advance Celgenes pipeline of innovative cancer therapies.
The acquisition culminates a 2011 strategic alliance between Celgene and Quanticel. Over the course of the three-and-a-half year alliance,... More
